Rolling Collaborative Reviews (RCR)
Please access the RCR project plan and all separate RCR documents, updated on a monthly or bi-monthly basis, in the following table.
Note: With the official end of EUnetHTA Joint Action 3 it has been decided, in consultation with the responsible authors, to discontinue the updating and publication of Rolling Collaborative Reviews on COVID-19 as of October 2021. Please note that for RCR20 on High-dose vitamin D and RCR21 on Mavrilimumab a final update may follow, depending on publication of available data.
Disclaimer: The EUnetHTA 21 Secretariat will be solely responsible for the publication of the remaining RCRs, but not their content.
*For monthly updated RCRs, the RCR authors search for new available evidence on a monthly basis. If new evidence is available, an updated report is published. In the case that no new evidence can be identified, no update is published, and the search is repeated in the subsequent month.
For bi-monthly updated RCRs, the RCR authors search for new available evidence every other month. If new evidence is available, an updated report is published. In the case that no new evidence can be identified, no update is published and the search is repeated after 2 months.
Please access a description of methods used in the RCR process here.
Stopping & Starting Rules for RCR
Stopping rule 1:
The compound is in EMA’s marketing authorization process or has a positive marketing authorization decision.
Stopping rule 2:
No clinical benefit: ≥ 2 RCTs OR treatment arms in platform trials (e.g., RECOVERY) with negative efficacy and/or safety results in the indication and population under review (phase III, of high or moderate quality/ high or moderate certainty of evidence, well powered).
OR ≥1 RCT with negative efficacy and/or safety results in the indication and population under review (phase III, of high or moderate quality/ high or moderate certainty of evidence, well powered) AND stopped enrollment of participants to the treatment arm of interest in a platform trial (e.g., RECOVERY) because no evidence of beneficial effects.
Starting rule 1:
Published results from ≥ 1 phase III RCT with positive efficacy and safety results in the indication and population under review (high or moderate quality, non peer-reviewed or peer-reviewed article).
Starting rule 2:
Upcoming (promising) evidence of ≥ 2 phase III trials.
Starting rule 3:
Compound included as trial drug in a platform trial on COVID-19 treatments.
Starting rule 4:
Combination therapy of ≥ 2 promising pharmaceuticals – the combination will be reviewed as a separate intervention.
Starting rule 5:
Interest from ≥ 2 EUnetHTA Partners (via survey) OR Interest from MAH to seek marketing approval OR Interest from EC, HTA Network or EUnetHTA Stakeholder Groups.
Rapid Collaborative Reviews
Please access the Rapid Collaborative Reviews in the following table.
Remdesivir for the treatment of COVID-19
National HTA Organisation Treatment Links
Links will be published here that relate to relevant partner organisation outputs on Covid-19.
Austrian Institute for Health Technology Assessment (AIHTA) – Horizon scanning for Covid-19 treatments:
Plasmapheresis of convalescent plasma to confer passive immunity
Evidence Summary for COVID-19 Clinical Samples
This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.
©2021 EUnetHTA All rights reserved.